Cancer Therapy

DNABarrier cancer treatment licensed to Chinese biotechnology corporation

Published in Health and Medicine Week, August 2nd, 2004

Mologen announced licensing of its dSLIM-based DNABarrier II to the Chinese biotechnology corporation Starvax Inc. of Beijing, PR China.

DNABarrier II is one of three applications currently under development using the dSLIM immunomodulator technology, developed and patented by Mologen. Following signature of a detailed term sheet, a first installment of 0.4 Mill Euro was received by Mologen.

This licensing deal is for Mologen the first financially important outcome from strategic alliances with biopharmaceutical companies and investors in China.

The license embraces the use of DNABarrier II in treatments of several major cancers,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-08-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry